These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12395930)

  • 21. Phosphorylation of Galpha11 protein contributes to agonist-induced desensitization of 5-HT2A receptor signaling.
    Shi J; Zemaitaitis B; Muma NA
    Mol Pharmacol; 2007 Jan; 71(1):303-13. PubMed ID: 17056873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A second-site suppressor strategy for chemical genetic analysis of diverse protein kinases.
    Zhang C; Kenski DM; Paulson JL; Bonshtien A; Sessa G; Cross JV; Templeton DJ; Shokat KM
    Nat Methods; 2005 Jun; 2(6):435-41. PubMed ID: 15908922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and manufacture of monoclonal antibodies for radioimmunotherapy.
    Hale G; Berrie E; Bird P
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):258-66. PubMed ID: 15640789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal antibodies, cytokines and fusion proteins in the treatment of malignant disease.
    Hank JA; Albertini MR; Sondel PM
    Cancer Chemother Biol Response Modif; 1999; 18():210-22. PubMed ID: 10800484
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluation of the catalytic mechanism of the p21-activated protein kinase PAK2.
    Wu H; Zheng Y; Wang ZX
    Biochemistry; 2003 Feb; 42(4):1129-39. PubMed ID: 12549935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Supervision of multiple signaling protein kinases by the CK2-Cdc37 couple, a possible novel cancer therapeutic target.
    Miyata Y; Nishida E
    Ann N Y Acad Sci; 2004 Dec; 1030():150-7. PubMed ID: 15659792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene therapy using antisense oligodeoxynucleotides labeled with Auger-emitting radionuclides.
    Kairemo KJ; Tenhunen M; Jekunen AP
    Cancer Gene Ther; 1998; 5(6):408-12. PubMed ID: 9917096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3.
    Jia LT; Zhang LH; Yu CJ; Zhao J; Xu YM; Gui JH; Jin M; Ji ZL; Wen WH; Wang CJ; Chen SY; Yang AG
    Cancer Res; 2003 Jun; 63(12):3257-62. PubMed ID: 12810656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell cycle regulatory protein p27KIP1 is a substrate and interacts with the protein kinase CK2.
    Tapia JC; Bolanos-Garcia VM; Sayed M; Allende CC; Allende JE
    J Cell Biochem; 2004 Apr; 91(5):865-79. PubMed ID: 15034923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiolabeling of receptor ligands by chemical incorporation of phosphorylation sites.
    Inglese J; Glickman JF
    Anal Biochem; 1999 Oct; 274(1):104-9. PubMed ID: 10527502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oligoradionuclidetherapy using radiolabelled antisense oligodeoxynucleotide phosphorothioates.
    Kairemo KJ; Tenhunen M; Jekunen AP
    Anticancer Drug Des; 1996 Sep; 11(6):439-49. PubMed ID: 8836109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimization of Fc-mediated effector functions of monoclonal antibodies.
    Strohl WR
    Curr Opin Biotechnol; 2009 Dec; 20(6):685-91. PubMed ID: 19896358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic antibodies: magic bullets hit the target.
    Gura T
    Nature; 2002 Jun; 417(6889):584-6. PubMed ID: 12050630
    [No Abstract]   [Full Text] [Related]  

  • 35. Improving the tumor specificity and retention of antibody-based molecules.
    Adams GP
    In Vivo; 1998; 12(1):11-21. PubMed ID: 9575421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From monoclonal antibodies to peptides and molecular recognition units: an overview.
    Serafini AN
    J Nucl Med; 1993 Mar; 34(3 Suppl):533-6. PubMed ID: 8441052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential phosphoprotein labelling (DIPPL) using 32P and 33P.
    Tolkovsky AM; Wyttenbach A
    Methods Mol Biol; 2009; 527():21-9, xi. PubMed ID: 19241002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers.
    Bhakta S; Raab H; Junutula JR
    Methods Mol Biol; 2013; 1045():189-203. PubMed ID: 23913148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis of 32P-labelled protein probes using a modified thioredoxin fusion protein expression system in Escherichia coli.
    Delucchi AB; Jensen KA; Chan WK
    Biomol Eng; 2003 Jan; 20(1):1-5. PubMed ID: 12485679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A method for probing the topography and interactions of proteins: footprinting of myoglobin.
    Zhong M; Lin L; Kallenbach NR
    Proc Natl Acad Sci U S A; 1995 Mar; 92(6):2111-5. PubMed ID: 7892233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.